dpp-4 inhibitors vs. glp-1 agonist receptor agonists or inhibitors: How to guide the clinician? GLP-1 receptor agonist versus DPP-4
Description
The patient takes ten times the intended dose
Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
One theoretical advantage of the GLP-1 approach is that it modulates rather than suppresses the immune system
doi:10.1254/fpj.21052 12
In rodent models of stroke, the number of CD3+ T cells reached a peak on day 7 after permanent middle cerebral artery occlusion (pMCAO), followed by a significant proliferative phase (65)
